anti-CEA CAR-T cells
Phase 1Cell therapy
anti-CEA CAR-T cells is one of 9 biologic programs targeting Liver Metastases. It is currently in Phase 1.
1
Indications
6
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Liver Metastases
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 2
Avastin
RochePhase 2
Camptosar
PfizerPhase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 2
5-Fluorouracil
Merck & Co.Phase 2
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 2
anti-CEA CAR-T cells
SSorrento Therapeutics, Inc.
Phase 1
Definity
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver Metastases4 trials
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Recruiting·—·Phase 1·NCT05240950·18 enrolled
Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-CEA CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- SSorrento Therapeutics, Inc.